中药治疗COVID-19附加疗效的系统评价与Meta分析
该系统评价与Meta分析检索截至2020年4月15日的文献,纳入19项研究共1474例COVID-19患者,评估中药或中药联合治疗的疗效与安全性。结果显示联合中药在整体临床有效率、CT改善、转重率、RT-PCR转阴率及症状消失率方面优于对照组,但住院时间和不良反应率无统计学差异,证据质量极低至低。
要点
- 联合中药可能提高COVID-19整体临床有效率和CT改善率。
- 联合中药可能降低转重/危重比例并提高RT-PCR转阴率。
- 住院时间和不良反应率与对照组无显著差异,证据质量低。
核心结论
- 中西医结合治疗COVID-19可能有效控制症状并降低疾病进展率,但证据质量低。
研究设计与样本
- 系统评价与Meta分析,检索CNKI、CBM、万方、PubMed、Cochrane Library、Embase等数据库从建库至2020年4月15日。
- 纳入随机对照试验、队列研究和病例对照研究,共19项研究1474例患者。
主要发现
- 整体临床有效率OR=2.67(95%CI 1.83-3.89,I2=0%)。
- CT扫描改善OR=2.43(95%CI 1.80-3.29,I2=0%)。
- 转重/危重比例OR=0.40(95%CI 0.24-0.67,I2=17.1%)。
- RT-PCR转阴率OR=2.55(95%CI 1.06-6.17,I2=56.4%)。
- 症状(发热、咳嗽、乏力)消失率联合中药组更优。
关键数值与推荐
- 住院时间WMD=-0.46(95%CI -3.87-2.95,I2=99.5%),组间无统计学差异。
- 不良反应率OR=1.21(95%CI 0.48-3.07,I2=43.5%),组间无统计学差异。
- 证据质量极低至低。
临床怎么用
- 在COVID-19治疗中可考虑联合中药以改善症状和降低转重风险。
- 需结合低证据质量谨慎解读,并监测不良反应。
局限性
- 纳入研究证据质量极低至低。
- 异质性较高(如住院时间I2=99.5%,RT-PCR转阴率I2=56.4%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chinese herbal medicine (CHM) is thought to be a potential intervention in the treatment of coronavirus disease (COVID-19). PURPOSE: This study aimed to investigate the efficacy and safety of CHM or CHM combination therapy for COVID-19. STUDY DESIGN: Systematic review and meta-analysis METHODS: We searched for relevant studies in the CNKI, CBM, Wanfang Data, PubMed, Cochrane Library, Embase, and other resources from their inception to April 15, 2020. Randomized controlled trials, cohort studies, and case-control studies on CHM or CHM combination therapy for COVID-19 were included. Meta-analysis was performed according to the Cochrane Handbook. RESULTS: Overall, 19 studies with 1474 patients were included. Meta-analysis showed that the overall clinical effectiveness (OR = 2.67, 95% CI 1.83-3.89, I2 = 0%), improvement in the CT scan (OR = 2.43, 95% CI 1.80-3.29, I2 = 0%), percentage of cases turning to severe/critical (OR = 0.40, 95% CI 0.24-0.67, I2 = 17.1%), reverse transcription-polymerase chain reaction (RT-PCR) negativity rate (OR = 2.55, 95% CI 1.06-6.17, I2 = 56.4%) and disappearance rate of symptoms (fever, cough, and fatigue) were superior by combined CHM treatment of COVID-19. However, there was no statistical difference between the two groups in terms of length of hospital stay (WMD = -0.46, 95% CI -3.87 - 2.95, I2 = 99.5%), and rate of adverse effects (OR = 1.21, 95% CI 0.48-3.07, I2 = 43.5%). The quality of evidence was very low to low. CONCLUSION: The combined treatment of COVID-19 with Chinese and Western medicine may be effective in controlling symptoms and reducing the rate of disease progression due to low quality evidence.
引用
- Luo X, Ni X, Lin J, et al. The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis. Phytomedicine. 2020. PMID: 32800699. doi:10.1016/j.phymed.2020.153282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。